Blueprint Medicines Corp (NASDAQ:BPMC)
| 91.60 Delayed Data As of 3:59pm ET |  +2.72 / +3.06%Today’s Change | 43.29 Today|||52-Week Range 92.63 | +14.34% Year-to-Date |
Latest BPMC News | Press Releases
Today’s Trading
| Previous close | 88.88 |
| Today’s open | 89.00 |
| Day’s range | 88.90 - 92.63 |
| Volume | 25,158 |
| Average volume (3 months) | 494,598 |
| Market cap | $4.9B |
Data as of 3:59pm ET, 09/29/2020
Growth & Valuation
| Earnings growth (last year) | -34.76% |
| Earnings growth (this year) | +149.00% |
| Earnings growth (next 5 years) | +34.00% |
| Revenue growth (last year) | +49.39% |
| P/E ratio | NM |
| Price/Sales | 57.61 |
| Price/Book | 9.34 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IOVAIovance Biotherapeut... | +0.38 | +1.19% |
| ALLOAllogene Therapeutic... | +0.49 | +1.32% |
| ARWRArrowhead Pharmaceut... | -0.23 | -0.53% |
| ---- |
Data as of 3:59pm ET, 09/29/2020
Financials
| Next reporting date | November 4, 2020 |
| EPS forecast (this quarter) | $9.25 |
| Annual revenue (last year) | $66.5M |
| Annual profit (last year) | -$347.7M |
| Net profit margin | -522.75% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
